28-day Levonorgestrel Oral Contraceptive

DRUG3 trials

Sponsors

Duramed Research, Teva Women's Health, Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Bone Mineral DensityFollicle CountFollicle DevelopmentFollicle SizeHemostasisOral ContraceptiveOvarian Follicle

Phase 1

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

CompletedNCT01291004

Teva Branded Pharmaceutical Products R&D, Inc.Follicle Count, Follicle Development, Follicle Size +2

Start: 2011-01-31End: 2012-03-31Updated: 2021-12-08

Phase 2

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

CompletedNCT00924560

Duramed ResearchBone Mineral Density

Start: 2009-06-30End: 2012-08-31Updated: 2014-10-22

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

CompletedNCT01252186

Teva Women's HealthHemostasis, Oral Contraceptive

Start: 2010-11-30End: 2011-12-31Updated: 2015-03-13